Unlike other models where concurrent blockade of PD-1 and Tim-3 delayed tumor progression as initial therapy in the context of high expression levels of these checkpoint proteins 25, we observed no additional benefit of the combination therapy (simultaneous Tim-3 and PD-1 blockade) as initial therapy over PD-1 blockade alone. This evidence concerns the gene HAVCR2 and neoplasm.